前列地尔或序贯使用贝前列素钠片对慢性肾脏病患者疗效的研究  

Clinical effect of alprostadil or combined with beraprost sodium on chronic kidney disease

作　　者：黄华星[1] 沈良兰[1] 张芬[1] 王琛[1] 房星星[1] 陈冬梅[1] 沈燕[1] 王荣[1] Huang Hua-xing Shen Liang-lan Chen Dong-mei Zhang Fen Wang Chen Fang Xing-xing Shen Yan Wang Rong(Department of Nephrology, The Second Affiliated Hospital of Nantong University, Jiangsu Nantong 226001)

机构地区：[1]江苏南通大学第二附属医院肾内科,江苏南通226001

出　　处：《四川生理科学杂志》2016年第3期163-165,共3页Sichuan Journal of Physiological Sciences

摘　　要：目的:慢性肾脏病患者在使用前列地尔或序贯使用贝前列素钠片治疗后的疗效观察。方法:筛查收住院的慢性肾脏病患者60例,均符合慢性肾脏病的临床诊断标准。入院后检测患者收缩压(Systolic pressure,SBP)、舒张压(Diastolic pressure,DBP)、体重指数(Body mass index,BMI)、血肌酐(Creatinine,SCr)、血尿素氮(Blood urea nitrogen,BUN)、血胱抑素C(Cystatin C,CysC)、尿微量白蛋白(Urine micro albumin,UMA)、肾小球滤过率(Glomerular filtration rate,eGFR)、血小板(Platelets)、凝血酶原时间(Prothrombin time,PT)。入院后随机分为2组:前列地尔治疗组(n=30):给予前列地尔治疗10μg·天^(-1),治疗2w;序贯治疗组(n=30):静脉注射前列地尔10μg·天^(-1),2周后,给予贝前列素钠片一日三次,每次40μg,治疗2w,结束后随访复查上述指标。结果:治疗前基线比较,两组BMI、SBP、DBP、BUN、CysC、Scr、eGFR、UMA、Platelets、PT之间无明显区别(P>0.05)。组内治疗前后比较:前列地尔组和序贯治疗组自身治疗前后BUN、CysC、Scr、eGFR、UMA治疗后均较治疗前明显改善(P<0.05)。治疗后两组比较:与前列地尔组相比,序贯治疗组eGFR、UMA明显改善(P<0.05)。结论:使用前列地尔治疗慢性肾脏病患者,能有效改善BUN、CysC、Scr、eGFR、UMA。使用贝前列素钠片序贯治疗后,对eGFR、UMA改善更明显,可有效的延缓了慢性肾脏病的发展。Objective：To study the impact of alprostadil or sequential use of beraprost sodium in patients with chronic kidney disease.Methods：Sixty patients with chronic kidney disease were screened and admitted.All patients meet the clinical diagnostic criteria for chronic kidney disease.Blood pressure（SBP/DBP）,body mass index（BMI）,blood urea nitrogen（BUN）,creatinine（Scr）,cystatin C（Cys C）,urine micro albumin（UMA）,glomerular filtration rate（eGFR）,platelet,prothrombin time（PT）were measured.All patients were randomly divided into 2groups：alprostadil group（n=30）,giving alprostadil in the treatment of 10g·day^（-1）,for two weeks;and sequential therapy group（n=30）,intravenous alprostadil 10g·day^（-1）,2weeks after,give beraprost sodium tablets three times a day,each time 40 g for two weeks.All indexs were reviewed after therapy.Result：BMI,SBP,DBP,BUN,CysC,Scr,eGFR,UMA,Platelets and PT have no difference between two groups at basal level（P〈0.05）.The comparison between basal level and after treatment within group,BUN,CysC,Scr,eGFR and UMA were all improved（P〈0.05）.After treatment,compared with alprostadil group,eGFR and UMA in sequential therapy group were significantly improved（P〈0.05）.Conclusion：Treatment of chronic kidney disease patients with alprostadil,can effectively improve the BUN,CysC,Scr,eGFR,UMA.And use beraprost sodium tablets sequential therapy,eGFR,UMA improvement is more obvious.Effectively delay the development of chronic kidney disease.

关 键 词：前列地尔 贝前列素钠片 慢性肾脏病 

分 类 号：R692[医药卫生—泌尿科学]